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ABSTRACT 
Trisomy 21 or Down syndrome (DS) is the most common cause of intellectual 
disability of a genetic origin. The Ts65Dn (TS) mouse, which is the most 
commonly used and best-characterized mouse model of DS, displays many of 
the cognitive, neuromorphological and biochemical anomalies that are found in 
the human condition. One of the mechanisms that has been proposed to be 
responsible for the cognitive deficits in this mouse model is impaired GABA-
mediated inhibition. Because of the well-known modulatory role of GABAA α5-
subunit-containing receptors in cognitive processes, these receptors are 
considered to be potential targets for improving the intellectual disability in DS. 
The chronic administration of GABAA α5-negative allosteric modulators has 
been shown to be procognitive without anxiogenic or proconvulsant side effects. 
In the present study, we use a genetic approach to evaluate the contribution of 
GABAA α5-subunit-containing receptors to the cognitive, electrophysiological 
and neuromorphological deficits in TS mice. We show that reducing the 
expression of GABAA α5 receptors by deleting one or two copies of the Gabra5 
gene in TS mice partially ameliorated the cognitive impairments, improved LTP, 
enhanced neural differentiation and maturation and normalized the density of 
the GABAergic synapse markers. Reducing the gene dosage of Gabra5 in TS 
mice did not induce motor alterations and anxiety or affect the viability of the 
mice. Our results provide further evidence of the role of GABAA α5 receptor-
mediated inhibition in cognitive impairment in the TS mouse model of DS.  
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INTRODUCTION 
It is well established that the GABAA receptor plays an important role in learning 
and memory processes. Non-selective positive allosteric modulators (PAMs) of 
the GABAA receptor, such as benzodiazepines, disrupt learning and memory 
processes [1-3], while non-selective antagonists and negative allosteric 
modulators (NAMs) improve cognitive processes [4-7]. In addition, non-selective 
GABAA NAMs, such as DMCM, increase long term potentiation (LTP) [8], 
whereas nonselective GABAA positive allosteric modulators (PAMs) (e.g., 
diazepam) impair LTP [9]. 
Among the different GABAA receptor subtypes, the GABAA α5-subunit-containing 
receptors, which are predominantly expressed in the hippocampus [10-13], are 
mainly localized extra-synaptically and generate long-lasting tonic currents [14-
17]. These receptors have been demonstrated to play an important modulatory 
role in learning and memory processes.  
Studies have demonstrated that homozygous (-/-) knockout mice lacking the 
Gabra5 gene show an improvement in cognitive processes [18, 19], thereby 
providing genetic evidence supporting that this receptor subtype plays a role in 
cognition. In addition, α5(H105R) knock-in mice showed a decreased expression 
of the GABAA α5 receptor in the hippocampus, which induced an enhancement 
in hippocampus-dependent learning and memory [20] and fear conditioning [21]. 
These findings, together with the restricted expression pattern of the GABAA α5 
receptors, makes these receptors attractive targets for the pharmacological 
enhancement of learning and memory [22, 23]. Several GABAA α5 NAMs, 
including L-655708, α5IA, MRK-016 and RO4938581, have been shown to 
improve learning and memory in preclinical studies [22, 24, 25]. In addition, α5IA 
was shown to restore ethanol-induced cognitive impairments in healthy 
volunteers [26].    
Down syndrome (DS) is the most common cause of an intellectual disability of a 
genetic origin [27, 28]. To understand the neurobiological basis of the cognitive 
impairments found in DS and develop therapeutic strategies to reduce these 
alterations, several murine models of DS have been developed. Among these 
models is the Ts65Dn (TS) mouse, which bears a partial trisomy of a segment of 
MMU16, which extends from the Mrp139 to the Znf295 genes and contains 
approximately 92 genes that are orthologous to the human chromosome 21 
(HSA21) genes [29]. Additionally, TS mice carry a trisomy of ~10 Mb of MMU17 
containing 60 genes that are nonhomologous to HSA21 [30, 31]; thus, these 
genes are not relevant to DS and may confound phenotypic consequences. 
Although the TS mouse is not the ideal model from a genetic point of view, it 
recapitulates many fundamental features of DS, including cognitive deficits and 
alterations in brain morphology and function [32-34]. Several other segmental 
trisomic models of different segments of MMU16, 17 and 10 have been created 
[see 31, 32, 34]. A comparison of phenotypes in TS mice with those of other 
partial trisomic models suggests that the set of genes triplicated in this model 
contributes to several DS phenotypes, including cognitive and neuroanatomical 
impairments [34]. For these reasons, most previous studies on DS structural and 
functional alterations have been performed on the TS mouse.  
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Although many of the neuromorphological alterations that are present in the TS 
mouse are likely partially responsible for their cognitive deficits, including the 
changes in the size, morphology and cellular density of different brain areas and 
the alterations in pre- and post-natal neurogenesis, dendritic structures and the 
morphology of synapses and spines [see 32, 34], abnormal synaptic plasticity 
(reduced hippocampal LTP and increased LTD) has been proposed to be a key 
mechanism underlying the intellectual disabilities in TS mice [35-37].  
In addition, several studies have demonstrated that in this murine model of DS, 
there is altered synaptic inhibition, which is mediated by the GABAA receptor [36-
40]. The administration of non-selective GABAA antagonists to TS mice rescued 
the deficits in LTP and the hippocampal-mediated memory impairments in the TS 
mice [41-43]. However, these drugs are not adequate candidates for the 
treatment of learning impairments in the DS population due to their anxiogenic 
and proconvulsant effects.  
The identification of the different functional roles of GABAA receptor subtypes 
suggests that receptor subtype-selective compounds could overcome the 
limitations of non-selective GABAA receptor modulators. The administration of the 
α5-selective NAMs α5IA and RO4938581 rescued the cognitive deficits in TS 
mice [44, 45]. In addition, the chronic administration of RO4938581 rescued the 
deficits in hippocampal synaptic plasticity, enhanced neurogenesis in the dentate 
gyrus and the granular cell density, and normalized the density of hippocampal 
GABAergic boutons in TS mice [40, 45]. Importantly, none of these compounds 
are proconvulsant or anxiogenic [40].  
Although Gabra5, which is the gene that encodes the α5 subunit of the GABAA 
receptor, is not localized in HSA21 or in the segment of MMU16 that is triplicated 
in the TS mouse and there is no evidence of alterations in the density of this type 
of receptor in this model of DS [40, 45], the impaired GABA-mediated inhibition 
could be mediated via the GABAAα5 subtype, which is abundant in the 
hippocampus. To test this hypothesis, in this study, we used a genetic approach 
to specifically reduce the inhibition that is mediated by these receptors in the TS 
mouse by deleting one or two copies of the Gabra5 gene. We crossed female TS 
and euploid (control, CO) mice with male Gabra5 knockout mice and performed 
a behavioral, electrophysiological and neuromorphological characterization of the 
progeny (TS and CO mice carrying 2, 1 or 0 functional copies of the Gabra5 
gene). 
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MATERIAL AND METHODS 
Animals 
This study was approved by the Cantabria University Institutional Laboratory 
Animal Care and Use Committee and carried out in accordance with the 
Declaration of Helsinki and the European Communities Council Directive 
(86/609/EEC).  
Ts(17<16>)65Dn (TS) mice were generated by repeated backcrossing of 
B6EiC3Sn a/A-Ts(17<16>)65Dn females with C57BL/6Ei x C3H/HeSNJ 
(B6EiC3Sn) F1 hybrid (CO) males at the animal facilities of the University of 
Cantabria.  
Because the Gabra5 (α5 subunit of the GABAA receptor) gene is located in MMU7 
and its orthologous human gene is located in HSA15, the TS progenitors carry 
two alleles of this gene. TS females were crossed with heterozygous males 
carrying a mutated copy of the Gabra5 gene (see figure 1a). Gabra5 KO mice 
were generated as previously described (gl-α5-KO, Rodgers et al., 2015) and 
provided by F. Hoffmann-La Roche Ltd. (Basel, Switzerland).  
From these crossings, a first generation (F1) was obtained, including the following 
four mouse genotypes: TS with two copies of Gabra5 (TS +/+), TS with a single 
functional copy of Gabra5 (TS +/-), CO with two copies of Gabra5 (CO +/+) and 
CO mice with a single functional copy of Gabra5 (CO +/-). 
Female TS +/- mice were then crossed with male CO +/- mice to obtain TS and 
CO mice (F2) with two functional copies, one functional copy or no functional 
copies of Gabra5 (i.e., TS +/+, CO +/+, TS +/-, CO +/-, TS -/- and CO -/- mice, 
see figure 1a). 
To determine the presence of the trisomy, animals were karyotyped using real-
time quantitative PCR (qPCR) as previously described [46]. Because the 
C3H/HeSnJ mice carry a recessive mutation that leads to retinal degeneration 
(Rd) [47], all animals were genotyped by standard PCR to screen for mice 
carrying this gene.  
To determine the number of functional copies of the Gabra5 gene carried by each 
animal, their genomic DNA was amplified by standard PCR following the protocol 
described by Rodgers et al. [48]. 
Mice were housed in groups of two or three in clear Plexiglas cages (20 x 22 x 
20 cm) under standard laboratory conditions with a temperature of 22 ± 2 °C, 12-
hour light/dark cycle and free access to food and water. The light/dark cycle was 
inverted to allow for the behavioral studies to be conducted during the active 
period of the mice.  
In this study, two cohorts of male mice were used (see Supplementary table 1). 
The first cohort was used to determine the effect of the gene dosage of Gabra5 
on cognition, behavior and neuromorphology in the TS and CO mice. The second 
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cohort of animals was used to assess the GABAA α5 receptor density in the 
different Gabra5 genotype groups by autoradiography. 
The behavioral experiments were performed with a total of 66 4- to 5-month-old 
mice (8-13 animals per group; see Supplementary table 1). After the completion 
of these studies, the mice were sacrificed at the age of 5-6 months; 6 animals 
from each group were used for the histological experiments. In addition, seven 6-
month-old animals per group were used for the autoradiography experiments (2-
7 animals per group). The researchers were blinded to the genotype and 
karyotype throughout the entire assessment.  
 
Viability of the different groups of mice and somatometry 
The viability of the different groups of mice born from the crossings of female TS 
+/- and male +/- mice was assessed by quantifying the number of animals with 
each karyotype and genotype born in each litter. In total, 100 male mice, born in 
28 litters, were analyzed. 
The effect of the karyotype and the genotype on the weight of the animals was 
evaluated once a month from weaning to the age of 5 months in 10 mice from 
each experimental group. 
 
Quantification of GABAA α5 receptors: in vitro autoradiography 
To evaluate whether the gene dosage of Gabra5 led to changes in the number of 
GABAA α5 receptors, the occupancy of GABAA α5 receptors was quantified using 
a specific radioligand.  
Mice were sacrificed by cervical dislocation, and their brains were rapidly 
removed and stored at -20 °C. The brains were subsequently cut into 10 µm-thick 
coronal sections with a cryostat and mounted on HistoBond glass slides 
(Marienfeld, Lauda-Königshofen, Germany).  
To perform the autoradiographic marking, a tritiated radioligand with a high affinity 
for GABAAα5 receptors, [3H] RO 15-4513 (synthesized in the isotope laboratory 
of F. Hoffmann-La Roche, Basel, Switzerland), was used following the protocol 
described by Sur et al. [49]. 
The slides were preincubated in a Ringer buffer with a pH of 7.4 (Sigma Aldrich, 
St Louis, MO, USA) at room temperature for 20 min, followed by an incubation 
with 0.94 µl of [3H] RO 15-4513 (specific activity: 47.2 Ci/mmol) in 400 ml of the 
Ringer buffer (pH 7.4) for 1 hour. This procedure was performed in duplicate for 
each animal. Non-specific binding was defined in a single sample per mouse 
under the same conditions described previously, but 10 µM of flunitrazepam 
(Sigma Aldrich) were added. The slides were then washed twice for 2 min in the 
Ringer buffer at 4 °C, followed by four immersions of the samples in distilled water 
at 4 °C. The samples were dried by a cold air current for 3 hours, and they were 
then exposed to tritium sensitive photographic films (Biomax MR Kodak, Madrid, 
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Spain) for 3 months at 4 °C in hermetic imaging plates (Kodak X-Omatic 
cassetteTM, USA). 
The autoradiograms were scanned and quantified by optical densitometry using 
the image analysis software Scion Image (Scion Corporation, Maryland, USA).  
The values of the receptor densities were obtained by exposing the films to 
different tritium-sensitive standards (Autoradiographic [3H]-micro-scaleTM y 
[14C]-micro-scale, Amersham, U.K.). The densitometric quantification of these 
impressions with the corresponding concentrations of the isotope allowed to 
obtain a calibration curve that was used to perform the first transformation of the 
gray tissue densities into their equivalent nCi/mg. After subtracting the 
background values and the non-specific binding, the obtained experimental 
values were transformed into the fmol/mg of the tissue according to the specific 
activity of [3H] RO 15-4513 (47.2 Ci/mmol). Finally, the density of the binding sites 
(Bmax) was calculated and expressed as the fmol/mg of the tissue according to 
the radioligand KD (0.1 nM). 
Cognitive studies 
 
1. Morris water maze 
The Morris Water Maze test was performed to evaluate spatial learning 
using the platform relocation protocol [50-53] that was described by 
Corrales et al. [54]. Briefly, the animals were tested in 12 consecutive daily 
sessions consisting of eight acquisition sessions (platform submerged), 
followed by four cued sessions (platform visible). Each session consisted 
of 8 trials, and the platform position was changed from session to session. 
Each trial terminated when the mouse located the platform or 60 s had 
elapsed. All trials were videotaped with a camera located 2 m above the 
water level. An AnyMaze computerized tracking system (Stoelting, Wood 
Dale, IL, USA) was used to analyze the swimming trajectories, escape 
latency, thigmotaxis and swimming speed of each animal in each trial.  
 
 
2. Fear Conditioning 
The fear conditioning experiment procedure was performed as described 
by Salehi et al. [55]. Briefly, contextual and tone-cued fear conditioning 
tests were performed using the Fear Conditioning apparatus (Stoelting) 
and the AnyMaze Video Tracking System (Stoelting). The mice underwent 
three days of testing as follows: a training day, a tone-cued in a novel 
context testing day and a contextual testing day. On the first day, the mice 
underwent a training session in which each mouse received five tone (70 
dB, 2 kHz, 20 sec)-shock (0.5 mA, 50 Hz, 2 sec) pairings. On the second 
day, each mouse was placed in a novel context for 3 min and was 
presented with three tone exposures without any shocks. On the final day, 
each mouse was placed in a context that was similar to that in the training 
8 
 
day for 5 min without any tones or shocks. The freezing behavior of the 
mice in each condition was quantified on both testing days. 
 
Histological and stereological procedures 
The animals were deeply anesthetized with pentobarbital (50 mg/kg) and 
transcardially perfused with saline, followed by 4% paraformaldehyde. 
Subsequently, the brains were postfixed in 4% paraformaldehyde overnight at 4 
°C and transferred to 30% sucrose. The brains were frozen on dry ice and 
coronally sliced with a cryostat (50-µm thick sections). Series of brain slices, 
comprising 1 section for every 9 slices, were used for the immunohistochemistry 
protocol. A 1-in-9 series of coronal sections was randomly selected and subjected 
to Nissl staining using the Cavalieri method, as previously described [56], to 
calculate the subgranular zone (SGZ) area and the dentate gyrus (DG) volume. 
 
1. Density of GABAergic synapse markers (VGAT immunofluorescence) 
One-in-nine serial 50-µm sections of the mice brains were used to determine the 
density of a GABAergic synapse marker. The sections were preincubated in 
PBT/BSA, and dual immunohistochemistry was performed. The GABAergic 
boutons were labeled using a goat anti-GABA vesicular transporter antibody 
(VGAT, 1:100 (Santa Cruz Biotechnology, Dallas, TX, USA)), followed by 
additional labeling with a donkey anti-goat Alexa Fluor® 594-conjugated antibody 
(1:1,000; Invitrogen, Carlsbad, CA, USA). 
Measurements were performed on images obtained using a confocal microscope 
(Leica SP5). Four sections per animal were used, which constituted the entire 
hippocampus, and one random area in the hippocampus per section was 
measured. The image analysis was performed using the ImageJ software as 
previously described [45], and the percentage of the reference area that was 
occupied by VGAT-positive boutons was calculated. 
VGAT-positive boutons were quantified in the DG inner molecular layer (IML) 
(figure 1b). This area was chosen because it contains an important inhibitory 
microcircuit that participates in the modulation of the activity of the DG [57, 58]. 
In this zone, a large number of inhibitory synapses are established between 
axons from the commissural/associational pathway and the dendrites of proximal 
granular cells [59, 60]. In addition, the IML is likely the most plastic zone of the 
ML because it is the first area where the dendritic trees of newborn neurons arrive 
after neural maturation during adult neurogenesis [61]. The IML is also the only 
stratum to which the dendritic trees of some of these immature neurons arrive, 
as after performing their functions, they occasionally do not differentiate further 
and instead die. Therefore, the IML is an adequate area in which to evaluate 
inhibitory drive and changes in plasticity that can affect cognitive processes. 
 
2. Cell proliferation in the SGZ of the DG (Ki67 immunofluorescence) 
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Ki67 immunofluorescence was performed to identify proliferating cells. The 
sections were preincubated in PBT/BSA (PB containing 0.5% Triton X-100 and 
0.1% BSA), and immunohistochemistry was performed as previously described 
[56]. Briefly, free-floating sections were incubated with a primary rabbit anti-Ki67 
antibody (1:750; Abcam, Cambridge, UK) for two days at 4 °C. Subsequently, the 
slices were incubated overnight at 4 °C with a secondary antibody diluted to 
1:1,000 (donkey anti-rabbit-Alexa Fluor® 488; Molecular Probes, Eugene, OR, 
USA). The sections were counterstained with DAPI and mounted on gelatin-
covered slides for the analysis and imaging. The total number of Ki67-positive 
cells was counted under an optical fluorescence microscope (Zeiss Axioskop 2 
Plus, 40x objective) using the optical dissector method as previously described 
[56]. 
3. Neuronal differentiation (DCX and CLR immunofluorescence) 
Doublecortin (DCX) is a microtubule-associated protein implicated in neural 
differentiation and migration, and calretinin (CLR) is a calcium binding protein that 
is briefly expressed before full neuronal maturation. Double labeling of these cells 
allows the identification of different neurogenic populations: DCX+/CLR- cells 
correspond to 2b and 3 neurogenic precursors (i.e. cells undergoing late mitosis 
or in early postmitotic phases), while DCX+/CLR- cells are late postmitotic 
differentiating cells [62, 63]. 
One-in-nine series of 50-µm sections were used for the determination of the 
densities of the cells expressing immature markers (DCX and/or CLR). The 
sections were initially preincubated in PBT/BSA, and dual immunohistochemistry 
was subsequently performed. A goat anti-doublecortin antibody (1:250; Santa 
Cruz Biotechnology, Santa Cruz, CA, USA) and a rabbit anti-calretinin antibody 
(1:3000; Swant, Switzerland) were used as the primary antibodies. The primary 
antibodies were labeled with a donkey anti-goat Alexa Fluor® 594-conjugated 
antibody and a donkey anti-rabbit Alexa Fluor® 488-conjugated antibody (1:1000; 
Alexa Fluor®-conjugated antibodies purchased from Invitrogen, Carlsbad, CA, 
USA). The sections were subsequently imaged under a confocal microscope 
(Leica SP5). The quantification of the DCX- and CLR-expressing cells was 
performed according to stereological procedures using the physical dissector 
method. To evaluate the cells expressing the immature markers, six random 
dissectors per animal were used, comprising sections representative of the entire 
hippocampus. A series of 11 confocal images was serially recorded in each 
physical dissector. All immature cells were counted using the physical dissector, 
which has a square area with one side that lies on the “line” of the SGZ (figure 
1b). By dividing the number of counted immature cells by the length of the 
“subgranular” line, a reliable estimate of the cell density by “unit of SGZ” was 
obtained. The cell density of the immature neurons is presented as either DCX+ 
(DCX+/CLR-) or CLR+ (DCX+/CLR+ plus DCX-/CLR+). 
4. Granule cell counts (DAPI) 
The cells in the hippocampal granule cell layer (GCL; figure 1b) were counted in 
sections stained with 4’6-diamidino-2-phenylindole (DAPI, Calbiochem, Billerica, 
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MA, USA; 1:1,000) for 10 min in phosphate buffer (PB). The cell counts were 
obtained using a confocal microscope coupled to a physical dissector system as 
previously described [56]. Six dissector locations in each series were evaluated. 
Subsequently, a series of confocal images was serially recorded according to the 
general principles of the physical dissector and the unbiased stereology methods. 
The confocal images were analyzed using the ImageJ software which generated 
the total number of cells when the dissector brick was completed. To count the 
total number of cells in the GCL, a square dissector frame was randomly situated 
inside the GCL. To obtain the number of cells per unit of volume (cell density), 
the obtained cell number was divided by the reference volume of the dissector.  
Long-term potentiation  
LTP recordings were performed in the CA1/CA3 region (figure 1b) because 
GABAAα5 receptors are mainly localized to the extrasynaptic regions of the 
dendrites of pyramidal neurons of the hippocampal CA1 and CA3 regions, where 
they mediate tonic inhibition [15, 20, 64, 65]. 
Due to the low viability of the TS -/- animals (figure 1c), it was not possible to 
obtain the necessary number of mice to perform this experiment, and LTP was 
not assessed in this group. Six 6-month-old animals were used in each of the 
other experimental groups (TS +/+, TS +/-, CO +/+, CO +/-, CO -/-). The mice 
were decapitated, and the brains were rapidly removed. The hippocampi were 
dissected, and 400-µm slices were generated using a tissue chopper. The slices 
were allowed to recover for 1 hour in an interface chamber at room temperature 
in artificial cerebral spinal fluid (ACSF) containing 120 mM NaCl, 3.5 mM KCl, 2.5 
mM CaCl2, 1.3 mM MgSO4, 1.25 mM NaH2PO4, 26 mM NaHCO3 and 10 mM D-
glucose saturated with 95% O2 and 5% CO2. The field excitatory postsynaptic 
potentials (fEPSPs) were recorded from the CA1 stratum radiatum using a glass 
micropipette (1–4 MΩ) containing 2 M NaCl, and the Schaffer collaterals were 
stimulated using insulated bipolar platinum/iridium electrodes located >500 µm 
from the recording electrode. The stimulus strength was adjusted to evoke 
fEPSPs equal to 50% of the relative maximum amplitude without a superimposed 
population spike. After the stable baseline recordings (100-µs pulse duration, 
0.033 Hz), long-term potentiation (LTP) was induced by TBS (10 trains of 5 pulses 
at 100 Hz and intervals of 200 ms). The duration of the stimulation pulses was 
doubled during tetanus. The fEPSPs were amplified, bandpass filtered (1 Hz-1 
kHz) and stored in a computer using the Spike2 software program (Cambridge 
Electronic Design, Cambridge, UK). For the analysis, the fEPSP slopes were 
expressed as a percentage of the recorded baseline values. The results from 
several slices were expressed as the mean value ± SEM. 
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Statistical analysis 
The data obtained from the MWM test experiments were analyzed using a two-
way repeated measures ANOVA (‘session x karyotype x genotype’ or ‘trial x 
karyotype x genotype’). The LTP data were analyzed using an RM MANOVA 
(‘time x karyotype x genotype’).The remaining data were analyzed using a two-
way (‘karyotype’ x ‘genotype’) ANOVA. The mean values of each experimental 
group were compared post hoc using Bonferroni tests. The percentage of animals 
born in each experimental group (viability study) was analyzed using Chi-squared 
tests. All analyses were performed using SPSS for Windows version 22.0. 
(Armonk, New York, USA). 
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RESULTS 
Viability 
The number of animals born with each genotype significantly differed (χ2 
(d.f.=5)=20.26, p=0.0011; figure 1c) from the predicted Mendelian distribution 
(12.5% for the CO +/+, TS +/+, CO -/- and TS -/- animals and 25% for the CO +/- 
mice and TS +/- mice). Although the +/- animals doubled the percentage of the 
+/+ and -/- mice in both genotypes, the TS mice carrying the different gene 
dosages of the Gabra5 gene showed a marked reduced viability as has been 
previously demonstrated in numerous studies. In addition, while the percentage 
of animals with the CO +/+ genotype did not differ from that of the CO -/- animals 
(in both cases, they represented 50% of the number of the CO +/- animals 
(χ2(d.f.=2)=0.16, p=0.91)), the TS -/- animals showed a reduced viability (only 
approximately 3% of the animals born belonged to this genotype and karyotype) 
from that expected, although this effect did not reach statistical significance 
(χ2(d.f.=2)=0.84, p=0.65). Therefore, the karyotype, but not the genotype, affected 
the viability of the mice.  
 
Effects of reducing Gabra5 dosage on cognitive performance 
1. Morris water maze (MWM) 
Consistently with numerous reports, the TS mice had more difficulties in learning 
the platform position than the CO mice as they displayed larger latencies to 
escape from the MWM than the CO mice (ANOVA ‘karyotype’: F(1,60)=105.28, 
p<0.001; figure 2a). The reduction in the Gabra5 gene dosage had a significant 
effect in both the TS and CO mice however, this effect was more evident in the 
TS mice (ANOVA ‘genotype’: F(2,60)=6.89, p=0.002; ‘genotype x treatment’: 
F(2,60)= 2.80, p=0.069). The TS mice that had a single functional copy of this gene 
showed an improved performance compared with mice that had both copies, and 
this improvement was more evident in the TS animals without a functional copy 
of this gene. In the case of the CO mice, both groups of KO mice displayed a 
slight improvement in their performance in this test compared with the CO +/+ 
animals; however, no differences were evident between the CO +/- and the CO -
/- groups. It is possible that a floor effect prevented further improvements in the 
CO -/- group. 
These improvements in the performance in the MWM may be partially due to a 
recovery in their procedural learning. Figure 2b shows the time that the animals 
spent in the periphery of the pool. Reducing the gene dosage of Gabra5 in the 
TS mice dose-dependently improved their searching strategy (i.e., it reduced their 
thigmotactic behavior) (ANOVA ‘karyotype’: F(1,60)=177.01, p<0.001; ‘genotype’: 
F(2,60)=4.30, p=0.18; ‘karyotype x genotype’: F(2,60)= 1.99, p=0.14). This effect was 
not found in the CO mice. 
The enhancement in the spatial and procedural learning after reducing the gene 
dosage of Gabra5 is not due to motor or motivational effects since no significant 
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differences were found between the 6 groups of animals in the latency to reach 
the platform during the cued sessions (ANOVA ‘karyotype’: F(1,60)=2.99, p=0.089; 
‘genotype’: F(2,60)=1.93, p=0.15; ‘karyotype x genotype’: F(2,60)= 0.29, p=0.74; data 
not shown) or the swimming speed during the entire experiment (ANOVA 
‘karyotype’: F(1,60)=0.74, p=0.39; ‘genotype’: F(2,60)=0.48, p=0.61; ‘karyotype x 
genotype’: F(2,60)= 0.22, p=0.80; data not shown). These results are consistent 
with a lack of effects on sensorimotor abilities (Supplementary table 2), motor 
coordination in the Rotarod (Supplementary figure 1) or the weight of animals 
that carry different numbers of copies of this gene (Supplementary figure 4).  
In addition, the improvements in cognitive abilities found in TS animals 
homozygous or heterozygous for the Gabra5 gene are not likely to be due to an 
amelioration of their attentional deficits because the hyperactivity of these 
animals was not corrected in the open field (Supplementary figure 2), plus maze 
(Supplementary figure 3) or hole board tests (Supplementary table 3).  
 
2. Conditioned Fear 
The TS mice showed a deficit in their ability to remember the association between 
a tone and an aversive stimulus. While these animals presented a larger number 
of freezing episodes (ANOVA ‘karyotype’: F(1,60)=5.70, p=0.020; figure 2c), these 
episodes were of a shorter duration (F(1,60)=7.13, p=0.010; figure 2d), which is 
considered the most relevant index reflecting the memory of the association 
between the conditioned stimulus (the tone) and the unconditioned stimulus (the 
electric shock). The Gabra5 gene dosage did not exert any effect on the number 
of freezing episodes (ANOVA ‘genotype’: F(2,60)=1.23, p=0.29; ‘karyotype x 
genotype’: F(2,60)=2.00, p=0.14) or the time spent freezing (ANOVA ‘genotype’: 
F(2,60)=0.14, p=0.86; ‘karyotype x genotype’: F(2,60)=3.13, p=0.51) in the TS or CO 
mice.  
During the context conditioning session, the TS mice displayed a marked difficulty 
in remembering the association between the context and the aversive stimulus. 
Although the statistical analysis revealed that the number of freezing episodes 
did not differ significantly between the TS and CO mice (ANOVA ‘karyotype’: 
F(1,60)=0.98; p=0.32, figure 2c), this effect was likely due to the marked increase 
in these episodes in the TS +/- and TS +/+ mice. In addition, the post hoc analysis 
revealed that the TS +/+ mice displayed a much smaller number of these 
episodes than the CO +/+ mice (p<0.001). The TS mice also spent a shorter 
amount of time freezing during this session than the CO mice (ANOVA 
‘karyotype’: F(1,60)=7.88; p=0.007, figure 2d). The deficit in the context fear 
conditioning completely disappeared in the TS +/- and TS -/- mice because these 
two groups of animals increased the number of freezing episodes (ANOVA 
‘genotype’: F(2,60)=5.86, p=0.005) and spent more time freezing (F(2,60)=7.69, 
p=0.001) than the TS +/+ mice. In fact, the heterozygous and homozygous TS 
mice did not differ from the CO mice with the three genotypes in any of these 
variables (figures 2c and 2d). Despite the effect of the genetic manipulation in 
the TS animals, reducing one or both functional copies of the Gabra5 gene in the 
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CO mice did not exert any benefit in the context conditioning (ANOVA ‘karyotype 
x genotype’: freezing episodes, F(2,60)=9.29, p<0.001; time freezing F(2,60)=4.21, 
p=0.020). 
Differences in the anxiety displayed by these animals are not likely to play a role 
in these effects, as no differences were found in the motor or cognitive 
components of anxiety in the 6 groups of animals in the plus maze 
(Supplementary figure 2) or open field (Supplementary figure 3) tests. 
 
Putative mechanisms implicated in the changes in cognitive performance 
induced by reduced Gabra5 dosage: 
1. α5-containing GABAA receptors density 
No significant differences were found in the amount of α5-containing GABAA 
receptors between the TS +/+ and CO +/+ mice in any of the areas analyzed 
(‘ANOVA karyotype’: anterior CA1 F(1,37)=1.78, p=0.19; anterior CA3 F(1,37)=2.23, 
p=0.14; anterior DG F(1,37)=0.10, p=0.75; posterior CA1 F(1,37)=0.34, p=0.56; 
anterior Hc F(1,37)=1.99, p=0.16; mean of all structures F(1,37)=1.54, p=0.22; figure 
3).  
However, the TS +/- mice displayed fewer α5-GABAA receptors than the CO +/- 
mice in all structures (‘ANOVA karyotype x genotype’: anterior CA1 F(2,37)=6.46, 
p=0.005; anterior CA3 F(2,37)=6.31, p=0.005; anterior DG F(2,37)=3.68, p=0.038; 
posterior CA1 F(2,37)=4.96, p=0.014; anterior Hc F(2,37)=9.16, p=0.001; mean of all 
structures F(2,37)=8.86, p=0.001). These results may be due to an interaction 
between the Gabra5 gene and other genes or gene products that are 
overexpressed in the TS mice. 
Reducing the number of functional copies of the Gabra5 gene dose-dependently 
lowered the number of α5 GABAA receptors in both the TS and CO mice (‘ANOVA 
genotype’: CA1 F(2,37)=190.29, p<0.001; anterior CA3 F(2,37)=54.72, p<0.001; 
anterior DG F(2,37)=81.93, p<0.001; posterior CA1 F(2,37)=54.34, p<0.001; anterior 
Hc F(2,37)=167.34, p<0.001; mean of all structures F(2,37)=144.73, p<0.001). This 
effect was particularly evident in the anterior CA1 area (figure 3). 
 
2. Changes in inhibitory- excitatory balance: density of GABAergic synapse 
markers (VGAT immunofluorescence) 
As previously described by several groups, the TS mice displayed an increased 
area occupied by a marker of GABAergic synapses VGAT (ANOVA ‘karyotype’: 
F(1,30)=4.70, p=0.037; figure 4). Reducing the number of functional copies of the 
Gabra5 gene in the TS and CO mice dose-dependently reduced the area 
occupied by the VGAT+ boutons (ANOVA ‘genotype’: F(2,30)=13.82, p<0.001); 
however, this effect was more evident in the TS than that in the CO mice 
(‘karyotype x genotype’ F(2,30)=3.63, p=0.037). 
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3. Neurogenesis: cell proliferation, differentiation and survival 
3.1. Cell proliferation in the SGZ of the DG (Ki67 immunofluorescence) 
The TS mice displayed a reduced number of proliferating cells in the SGZ of the 
hippocampus (ANOVA ‘karyotype’: F(1,30)=21.10, p<0.001; figure 5). The 
reduction in the number of copies of the Gabra5 gene tended to increase the 
density of Ki67+ cells in the TS, but not in CO, mice; however, this effect did not 
reach statistical significance (ANOVA ‘genotype’: F(2,30)=0.36, p=0.70; ‘karyotype 
x genotype’ F(2,30)=1.35; p=0.27). Therefore, this effect is unlikely to account for 
the improvements in the cognitive performance in the two learning and memory 
tests described above that were found in the TS mice with a reduced Gabra5 
gene dosage. 
3.2. Neuronal differentiation (DCX and CLR immunofluorescence) 
The TS mice presented a lower density of cells during the initial stages of 
differentiation (DCX+/CLR- cells: ANOVA ‘karyotype’: F(1,30)=14.23, p=0.001; 
figure 6). In the later stages (DCX+/CLR+), the density of this population did not 
significantly differ between the TS and CO mice when all genotypes were 
considered (ANOVA ‘karyotype’: F(1,30)=2.21, p=0.14), which was likely due to the 
increased density found in the heterozygous and homozygous TS animals. 
However, the post hoc analysis revealed that the TS +/+ mice presented a lower 
density of DCX+/CLR+ cells than the CO +/+ mice. Reducing one or both copies 
of the Gabra5 gene significantly increased the density of both populations of 
immature cells in the TS and CO mice (ANOVA ‘genotype’: DCX+/CLR- 
F(2,30)=3.45, p=0.043; DCX+/CLR+ F(2,30)=3.44, p=0.043; ANOVA ‘karyotype x 
genotype’: DCX+/CLR- F(2,30)=0.41, p=0.66; DCX+/CLR+ F(2,30)=0.28, p=0.75; 
figure 6). These results suggest that reducing the function of the Gabra5 gene 
accelerates or increases the maturation of newly born cells. 
3.3. Granule cell counts (DAPI) 
The density of mature cells in the GCL of the hippocampus was reduced in the 
TS mice (ANOVA ‘karyotype’: F(1,30)= 55.08, p<0.001; figure 7). However, the 
ANOVA revealed a non-significant effect of genotype in the TS or CO mice 
(‘genotype’: F(2,30)=1.65, p=0.20; ‘karyotype x genotype’ F(2,30)=1.67, p=0.20); the 
post hoc comparisons between the TS animals with two copies of the Gabra5 
gene and those with one or no functional copy of this gene revealed that reducing 
its dosage leads to a significant increase in the number of DAPI+ cells in the TS, 
but not in the CO, mice. 
 
 
 
4. Synaptic plasticity: Long Term Potentiation 
Figure 8 shows that the induction of LTP was reduced in the TS mice compared 
with that in the CO mice (ANOVA ‘karyotype’: F(1,25)=4.11, p=0.049). This effect 
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was not too strong due to the positive effect of reducing the number of copies of 
the Gabra5 gene in the TS animals (see below). However, when the TS +/+ mice 
were compared with the CO +/+ mice, the former presented a stronger reduction 
in LTP (ANOVA ‘karyotype’: F(1,25)=12.65, p=0.002). 
When all groups were analyzed together, the RM MANOVA revealed that the 
genetic manipulation had no significant effect in the TS or CO mice (ANOVA 
‘genotype’: F(2,25)=2.29, p=0.11), and this result was due to the positive outcome 
in the LTP induction after reducing the Gabra5 gene dosage in the TS, but not 
the CO, mice (ANOVA ‘karyotype x genotype’: F(2,25)=4.38, p=0.043; Figure 8). 
The groups of CO mice carrying two, one or no functional copies of the Gabra5 
gene did not differ in the amount of LTP generated after TBS (‘ANOVA’ genotype’: 
F(2,15)=0.20, p=0.81). However, knocking out a copy of this gene in the TS mice 
led to a robust enhancement in LTP (F(1,10)=16.49, p=0.001). In fact, the TS +/- 
animals displayed a completely normalized LTP as their slopes did not 
significantly differ from those of the CO +/+ mice (F(1,10)=0.00, p=0.99). 
No significant differences were found between the 5 groups of mice in the basal 
values before the administration of TBS (ANOVA ‘karyotype’: F(1,25)=0.023, 
p=0.88, ‘genotype’: F(2,25)=0.46, p=0.63; ‘karyotype x genotype’: F(2, 25)=1.47, 
p=0.23; Figure 8). 
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DISCUSSION 
This study shows that genetically reducing the α5 GABAA-mediated inhibition 
ameliorated the cognitive deficits in TS mice. This genetic approach confirms 
previous findings regarding the role of the GABA-mediated inhibition in the 
cognitive deficits in TS mice and the procognitive effects of reducing this inhibition 
by targeting the GABAA α5 receptors. We characterized the behavioral, cognitive 
and neuromorphological effects of reducing the dosage of the Gabra5 gene in 
trisomic mice and their euploid littermates. 
In agreement with previous studies [66, 67], TS mice exhibited reduced viability 
with respect to CO mice. Although statistical analysis revealed no significant 
deviation from the expected Mendelian distribution in the percentage of animals 
with different dosages of the Gabra5 gene that were born, the extremely low 
viability of TS -/- animals (3%) suggests that this genetic manipulation might affect 
the viability of trisomic mice. An explanation for this finding could be that the 
interaction of Gabra5 with other triplicated genes aggravated the cardiovascular 
dysfunctions displayed by a larger number of TS mice that reduce their perinatal 
survival.  
 
Previous work has shown that knocking out the Gabra5 gene in wildtype mice 
improved their performance in different hippocampal-dependent tasks [18, 19]. In 
the TS mice, modifying the number of functional copies of the Gabra5 gene 
attenuated the well-known spatial learning and memory impairments found in the 
MWM. This effect was also evident in the CO mice, although it was much more 
pronounced in the trisomic mice likely because of the larger impairment found in 
these animals and/or a floor effect in the CO mice. The improvements in 
performance in the MWM were not due to improvements in motivation or motor 
abilities since no significant differences were found in the latency to reach the 
platform during the cued trials or the animals’ swimming speed. These effects are 
consistent with the lack of an effect of the Gabra5 gene dosage on motor 
coordination in mice of either karyotype as described in the Supplementary 
Results section. 
 
In the case of the TS mice, the enhancement in the procedural learning may have 
played an important role in the procognitive effects found in the MWM because 
the heterozygous and homozygous Gabra5 TS mice presented less thigmotactic 
behavior.  
Additionally, in the fear conditioning test, the TS mice showed impairments in 
both the cued and context conditioning. The reduction in the Gabra5 gene dosage 
completely rescued the context conditioning in the TS mice but did not have any 
effect on the cued conditioning. In rodents, the GABAA α5 receptors are mainly 
located in the hippocampus [10-13], and context conditioning is known to rely on 
the proper functioning of this structure, while the amygdala and other structures 
mediate cued conditioning [68, 69], which may explain these results. Studies 
performed in Gabra5 KO mice in which their performance in hippocampal-
independent tasks, such as delay fear conditioning and two-way avoidance, was 
unaltered [18-21] further support this hypothesis. 
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The enhancements in the cognitive performance of the heterozygous and 
homozygous TS and CO mice in the MWM and in the TS animals in the fear 
conditioning test are likely due to a reduction in the GABAAα5 receptor-mediated 
inhibition.  
However, reducing the Gabra5 gene dosage in TS animals only partially 
ameliorated their cognitive deficits. In the Morris water maze test, the rescue of 
the cognitively altered phenotype was not complete and might have been mainly 
mediated by decreased thigmotaxis. In the fear conditioning test, normalization 
of performance was only achieved in the contextual memory test after reducing 
the Gabra5 gene dosage, but this genetic manipulation did not have any effect 
on the memory abilities displayed by the different groups of TS mice in the cued 
conditioning test. Moreover, as shown in the Supplementary Material, reducing 
GABAAα5 receptor expression did not rescue the hyperactivity or the motor 
coordination deficits of TS animals. Therefore, reduction of GABAAα5 receptor-
mediated inhibition only partially improved specific cognitive domains (i.e., 
hippocampal-dependent spatial learning and context conditioning). 
 
Our autoradiographic results confirmed that reducing the number of functional 
copies of the Gabra5 gene dose-dependently lowered the density of α5 GABAA 
receptors in mice with both genotypes. However, the effect of removing a single 
copy of Gabra5 was larger in the TS +/- mice than that in the CO +/- mice in all 
structures analyzed. These results may be due to an interaction between the 
Gabra5 gene and other genes or gene products that are overexpressed in the TS 
mice. The greater reduction in the density of this type of receptor in the TS +/- 
mice than that in the CO +/- animals may be partially responsible for the greater 
cognitive benefits observed after knocking out this gene in the trisomic mice 
compared with those in the control mice.  
The density of the α5 GABAA receptors in the TS +/+ mice was similar to that in 
the CO +/+ mice. These results are consistent with other studies that showed that 
the TS and CO mice do not differ in the number of α5 GABAA receptors [45, 70] 
and with the fact that the Gabra5 gene is located in MMU7, and its orthologous 
human gene is located in HSA15; thus, this gene is not triplicated in the TS mouse 
or DS individuals. Therefore, the impairments in the neuronal plasticity and 
related cognitive problems in the TS mice cannot be attributed to the numbers of 
these receptors. However, it is possible that the enhanced GABA release in the 
hippocampus in TS mice results in a higher activity of these and other GABAA 
receptor subtypes.  
Altogether, these results suggest that although the density of this type of receptor 
is not responsible for the altered learning abilities in the TS animals, 
manipulations that reduce the impaired GABAA-mediated inhibition in these mice 
have procognitive effects. In fact, several studies have demonstrated the 
procognitive effects of the administration of different α5 selective and non-
selective NAMs in this model of DS [for a review see 40]. Pharmacologically 
modulating the GABAA α5 receptors with different NAMs improved spatial 
learning and memory and reduced the thigmotactic behavior, thereby improving 
navigation strategies [44, 45]. 
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The smaller beneficial effect of knocking out Gabra5 on the cognitive abilities in 
the CO mice compared with that in the TS mice described in this study is 
consistent with a study by Ballard et al. [25], who did not find improvement in 
working memory in control rats in the DMTP task or the MWM after a chronic 
RO4938581 treatment. Additionally, the NAM α5IA did not improve the cognitive 
performance of CO animals during the acquisition sessions in the MWM [37]. In 
contrast, RO4938581 improved the performance of unimpaired monkeys in the 
object retrieval task. These animals were exposed to the task infrequently to 
prevent asymptotic performance, thus allowing a window for improvement [25]. It 
is also possible that the precognitive effects of reducing GABAAα5 activity, 
genetically or pharmacologically, is more evident in those animals that have 
altered inhibition than in those that have an adequate balance between inhibitory 
and excitatory circuit influences. 
In the present study, the TS +/+ mice presented an enhanced density of the area 
occupied by a marker of GABAergic synaptic boutons, VGAT, in the DG IML. 
Although several studies have shown that TS mice display impaired neuronal 
plasticity that is partially due to altered GABAergic signaling [36-41, 71], the 
imbalance between excitatory and inhibitory activity is not uniform in the trisomic 
brain. An increase in GABAA-mediated transmission has been found in the DG of 
TS mice [36, 71] but not in the CA3 [72, 73] or CA1 [74, 75] hippocampal 
subfields, and tonic GABAergic inhibition is less efficient in the cerebellum of TS 
mice [76].  
In addition, studies evaluating GABAergic synaptic density in different areas of 
the TS brain suggest that the number of these synapses is differentially affected 
depending on the brain region analyzed. Electron microscopy studies in the 
temporal cortex and hippocampus of adult TS mice found a normal density of 
symmetric (inhibitory) synapses [77-79]. Similarly, immunohistochemical 
evaluation of GABAergic terminals confirmed normal density in the TS mouse 
DG. In contrast, an increased GABAergic synaptic density was found in the IML, 
granular layer and DG of TS mice [38, 45, 80]. The reasons for these 
discrepancies are not fully understood, but compensatory mechanisms after 
altered brain development occurs might account for these regional changes.  
The changes in the area occupied by VGAT+ boutons found in the present study 
and in previous studies [45, 80] are likely to be restricted to the area analyzed, 
and cannot be considered a generalized modification of synaptic inhibition. 
Future studies should also evaluate the effect of modifying GABAAα5 function 
and/or expression on GABAergic synaptic markers in other hippocampal areas. 
Recently it has been proposed that GABA might be excitatory rather than 
inhibitory in TS mice challenging the well-established concept of excessive 
GABA-mediated inhibition underlying cognition impairment in this mouse model 
of DS [81]. However, these data remains to be reproduced. 
Other murine models of DS with different sets of triplicated genes display 
excitatory-inhibitory balance anomalies similar to those found in TS mice. The 
Ts1Cje mouse presents abnormalities in the morphology of inhibitory synapses 
in the hippocampus and cortex [79, 82, 83]. The Dp16 model exhibits an increase 
in the expression in the cortex and hippocampus of the GAD67 and VGAT 
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proteins, implicated in inhibitory transmission [84]. These results suggest that the 
overexpression of one or several of the genes triplicated in the three models could 
be responsible for the altered inhibition found in DS mouse models. Among these, 
the Synj1 [85], Olig1 and Olig2 [74] and the Dyrk1A [80, 84] gene have been 
proposed to play a role in the excitatory/inhibitory imbalance found in trisomic 
animals.  
In the heterozygous TS +/- mice, the density of VGAT+ boutons was completely 
normalized, and this effect was more pronounced in the TS -/- mice. In the CO 
mice, the reduction in the number of functional copies of the Gabra5 gene also 
dose-dependently reduced the area that was occupied by VGAT+ boutons. This 
reduction in the inhibitory influence of GABAergic synapses could be one of the 
mechanisms underlying the cognitive enhancement found in mice of both 
karyotypes in the MWM and the fear conditioning test in the TS mice. Martínez-
Cué et al. [45] also demonstrated that a chronic administration of a α5 selective 
NAM reduced the area that was occupied by VGAT+ boutons in TS animals, 
thereby reducing the over-inhibition. 
Previous studies in Gabra5 KO mice suggested that the absence of α5 subunit is 
not compensated by an upregulation of α1, α2, or α3 subunits and that the 
pharmacology of hippocampal benzodiazepine sites remaining was unchanged 
[18]. Our data does not exclude that reduction of α5 subunits did not induce 
compensatory effects in TS mice but restoration of LTP in this mouse is in line 
with the role of this receptor subtype in controlling synaptic plasticity. Reduction 
of extrasynaptic GABAAα5 receptors in TS mice may have also impacted on the 
density and/or properties of their GABAergic synapses. It has been demonstrated 
that alterations in receptor assembly or subunit expression levels can indirectly 
alter synaptic localization and function [86]. In addition, tonic GABAA-mediated 
membrane depolarization has been shown to promote synapse formation [87].  
Because GABAA receptors regulate the proliferation, migration, differentiation 
and integration of new neurons [88-92], the decrease in the GABAA mediated-
inhibition in the TS mouse after knocking out the Gabra5 gene could play a role 
in the procognitive effects found in the TS animals by reducing functional and/or 
neuromorphological anomalies in their hippocampi. Tonic depolarizing GABAA 
responses by GABAergic Parvalbumin interneurons negatively regulate adult 
neurogenesis in the dentate gyrus (DG) of the hippocampus [93-95]. 
Although the present neuromorphological studies showed a tendency in which 
the density of proliferating (Ki67+) cells in the hippocampi of TS +/- and TS -/- 
mice was increased, this tendency did not reach statistical significance. 
Therefore, this effect is unlikely to account for the improvements in cognitive 
performance found in the heterozygous and homozygous TS mice. However, the 
reduced density of cells during late mitotic and early postmitotic stages 
(DCX+/CLR- cells) and during late postmitotic stages (DCX+/CLR+ cells) in the 
TS+/+/+ mice was completely rescued after knocking out both copies of the 
Gabra5 gene, which suggests that reducing the function of this gene accelerates 
or increases the maturation of newly born cells. When the density of the mature 
granule cells in the GCL of the hippocampus was evaluated, it was found that 
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reducing the dosage of the Gabra5 gene led to a significant increase in the 
number of DAPI+ cells in the TS, but not in the CO, mice, which could also play 
a role in the described cognitive enhancing effects.  
Proliferating, immature neurons in different stages of differentiation and mature 
granule cells appear to have different electrophysiological properties and roles in 
learning and memory processes [95-99]. Therefore, the enhanced maturation of 
newly born cells that was found after reducing the Gabra5 gene dosage in this 
study may be one of the mechanisms responsible for the enhancement in 
cognition that was induced by this genetic manipulation. However, the present 
results are not entirely consistent with our previous results in which after the 
chronic administration of RO4938581 to TS mice, a complete rescue of 
proliferating and mature cells was found, although the effect of this compound on 
the differentiating cells was not evaluated [45]. Therefore, the mechanisms by 
which the pharmacological and genetic reduction of the over-inhibition in TS mice 
induce the procognitive effects appear to be slightly different. Another explanation 
is that the genetic approach may lead to an adaptation or compensatory changes 
early in development, which is less visible in adulthood. 
There are numerous reports of the role of adult hippocampal neurogenesis in the 
stablishment of LTP and in learning and memory processes [100-103]; therefore, 
enhancing neurogenesis could enhance LTP and the cognitive abilities of TS 
mice. In agreement with numerous reports demonstrating that LTP is altered in 
the hippocampal CA1/CA3 and DG regions in TS mice due to altered GABA-
mediated activity [36, 37, 41, 82], the present study also showed a deteriorated 
LTP in the CA1/CA3 region of TS +/+ animals. 
A comparative evaluation of synaptic plasticity deficits in other DS mouse models 
has shown that LTP in the CA3/CA1 region was decreased in Ts1Cje, Dp16 and 
triple trisomic mice (Dp10/Dp16/Dp17), unchanged in Ts1Rhr and Dp10 mice and 
even significantly increased in Dp17 mice [104-107]. In the DG, LTP was impaired 
in Ts1Cje, Ts1Rhr and triple trisomic (Dp10/Dp16/Dp17) mice [82, 108]. Because 
Dp16 and triple trisomic mice (Dp10/Dp16/Dp17) show behavioral and synaptic 
plasticity deficits comparable to those found in TS mice [106-108], and Dp10 and 
Dp17 mice show normal (or even enhanced) performances [107], it is possible 
that the set of MMU16 syntenic genes overexpressed in TS and in Dp16 mice 
plays an important role in this altered synaptic plasticity.  
In the present study, the impairment to LTP presented by TS +/+ mice was 
completely rescued after reducing the Gabra5 gene dosage. The GABAA α5-
subunit-containing receptors are predominantly localized extra-synaptically in the 
dendrites of hippocampal CA1 pyramidal neurons [10-13] and generate long-
lasting tonic currents [14-17]. However, these receptors have also been detected 
at GABAergic synapses on the same dendrites of hippocampal pyramidal 
neurons and could, therefore, mediate phasic GABAergic inhibition as well [65]. 
Because tonic currents drive neuronal migration and maturation, axon growth, 
and synaptic plasticity [109-112], the reduction of the density of GABAAα5-
subunit-containing receptors in heterozygous or homozygous Gabra5 TS mice 
could be a mechanism partially responsible for the observed improvements in 
neurogenesis and LTP, thereby enhancing cognition in these animals. 
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However, reducing the number of functional copies of the Gabra5 gene did not 
have any significant effect on LTP in the CO mice, which is consistent with other 
studies that failed to find changes in LTP in Gabra5 KO mice [18, 20], except for 
under certain stimulation conditions [19].  
 
The differential effects of reducing the number of copies of the Gabra5 gene in 
the TS and CO mice on LTP may be one of the mechanisms implicated in the 
improved cognition that is found in the TS mice but is not as evident in the CO 
mice in the MWM and was absent in the fear conditioning test. These results are 
consistent with the normalization of LTP displayed by the TS animals after a 
chronic administration of RO4938581 without a significant effect in the CO 
animals [45]. However, other authors have reported that the chronic 
administration of α5IA or RO4938581 increases hippocampal LTP in normal 
rodents [25, 113]. As mentioned above, the discrepancies between the results of 
these reports and the present study may be due to the different backgrounds of 
the CO mice.  
Finally, the TS and CO animals that differently expressed the Gabra5 gene did 
not show alterations in anxiety or motor abilities (see Supplementary Results 
and Discussion). These results provide further support for the selectivity of the 
α5 receptor in cognitive functions and its role as a therapeutic target for learning 
and memory altered states.  
In summary, this study shows that reducing the number of functional copies of 
the Gabra5 gene in TS mice had effects that were similar to those observed 
following the chronic administration of an α5-selective NAM as follows: it 
induced a partial procognitive effect, improved LTP, enhanced neural 
differentiation and maturation and normalized the density of the GABAergic 
synapse markers. These effects were gene dose-dependent and were more 
evident in the TS mice than in the CO mice. In addition, modifying the gene 
dosage of Gabra5 did not induce motor alterations and anxiety or reduced the 
viability of the mice. Although the present work and the results from 
pharmacological studies support that reducing the GABAA mediated-inhibition is 
a good target for improving cognitive alterations in DS, the fact that all these 
studies have been performed in animal models of DS limit their translational 
value to the human condition. Thus far, there is no confirmation that there is an 
enhanced inhibition in the brains of individuals with DS. Thus, studies in 
humans are necessary to demonstrate the potential translational value of these 
findings. 
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FIGURE CAPTIONS 
 
Fig 1. Crossings performed to obtain the six genotypes of mice characterized in this 
study (a), schematic representation showing where in the hippocampus different 
experiments were performed (b), and percentage of animals born with each genotype 
(c). Dotted bars represent the expected probability of birth (Mendelian distribution) in 
each experimental group. ΦΦ: p<0.01 TS vs. CO χ2 ‘karyotype’. DG: dentate gyrus, 
GCL: granular cell layer, IML: inner molecular layer, ML: molecular layer, SGZ: 
subgranular zone. Quantification of VGAT+ boutons was performed in the IML, of 
Ki67+ cells in the SGZ and of DCX/CLR (+ and/or –cells) and of DAPI+ cells in the 
GCL of the DG. LTP induction and recordings were performed in the CA3/CA1 
hippocampal regions.  
 
Fig 2. The mean ± S.E.M. of the latency to reach the platform (a), the percentage of 
time spent in the periphery of the maze (b) during the acquisition sessions of the Morris 
water maze, the number of freezing episodes (c) and the time spent freezing (d) 
displayed by TS and CO mice with different gene dosage of the Gabra5 gene during 
the cued- and context- conditioning test sessions in the fear conditioning tests. *: 
p<0.05, **: p<0.01, ***: p<0.01 TS vs. CO, #: p<0.05; ##: p<0.01, ###: p<0.001 Gabra5 
+/+ vs. Gabra5 +/- or vs. Gabra5 -/-. Bonferroni tests following significant ANOVAs. Φ: 
p<0.05 TS vs. CO, ANOVA ‘karyotype’. 
 
Fig 3. Representative in vitro autoradiographical images of coronal brain sections in 
which the anterior hippocampus is observed from CO and TS mice with different gene 
dosages of the Gabra5 gene (a). The mean ± S.E.M. of the density of the α5 GABAA 
receptors as measured by in vitro [3H]-RO0154513 autoradiography in the anterior 
CA1, CA3, and DG; the mean of these three anterior hippocampal areas (anterior Hc) 
and the posterior CA1 area (b) and the mean of the specific radioligand binding found 
in all these hippocampal areas (c). *: p<0.05, **: p<0.01 TS +/- vs. CO +/-; #: p<0.05, 
##: p<0.01, ###: p<0.001 Gabra5 +/+ vs. +/- or +/+ vs. -/-; δ: p<0.05, δδ: p<0.01, δδδ: 
p<0.001 Gabra5 +/- vs. -/-. Bonferroni tests following significant ANOVAs.  
 
Fig 4. Representative images of the area occupied by the VGAT+ boutons in the DG 
IML in the 6 groups of mice (a) and the mean ± S.E.M of the area occupied by the 
VGAT+ boutons in this area of the hippocampus (b) in TS and CO mice with different 
gene dosages of the Gabra5 gene. *: p<0.05 TS vs. CO; #: p<0.05; ##: p<0.01 Gabra5 
+/+ vs. +/- or vs. -/-. Bonferroni tests following significant ANOVAs. 
 
Fig 5. Representative images of the Ki67+ staining in the SGZ of the hippocampus in 
the 6 groups of mice (a) and the mean ± S.E.M. of the density of the Ki67+ cells in the 
SGZ of the hippocampus in TS and CO mice with different Gabra5 gene dosages (b). 
***: p<0.001 TS +/+/+ vs. CO +/+/+. Bonferroni tests following significant ANOVAs. 
ΦΦΦ: p<0.05 TS vs. CO ANOVA ‘karyotype’. Arrowheads in (a) signal single Ki67+ 
cells. 
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Fig 6. Representative images of the number of DCX+/CLR- and DCX+/CLR+ positive 
cells in the DG in the 6 groups of mice (a) and the mean ± S.E.M of the density of the 
DCX+/CLR- cells and DCX+/CLR+ cells found in the hippocampus in the 6 groups of 
animals (b). *: p<0.05; **: p<0.01 TS +/+/+ vs. CO +/+/+, #: p<0.05 Gabra5 +/+ vs. +/- 
or -/-. Bonferroni tests following significant ANOVAs. ΦΦ: p<0.01 TS vs. CO ANOVA 
‘karyotype’. 
 
Fig 7. Representative images of DAPI+ cells in the GCL in the 6 groups of mice (a) and 
the mean ± S.E.M of the density of the DAPI+ cells in the GCL of the hippocampus in 
TS and CO mice with different dosages of the Gabra5 gene (b). ***: p<0.01 TS +/+/+ 
vs. CO +/+/+; #: p<0.05 Gabra5 +/+ vs. +/- or vs. -/-. Bonferroni tests following 
significant ANOVAs. ΦΦΦ: p<0.001 TS vs. CO ANOVA ‘karyotype’. 
 
Fig 8. Time courses of the initial slope of the field excitatory postsynaptic 
potentials (fEPSPs) recorded from the apical dendritic layer of the CA1 region in 
hippocampal slices after stimulating the Schaffer collateral commissural 
pathway at 30 s intervals. Following 20 min of stable baseline recording, a theta 
burst stimulus induced robust LTP in the hippocampal slices of the vehicle 
treated CO, but not TS, mice. Reduction in the gene dosage of Gabra5 resulted 
in an enhanced LTP in slices from TS, but not from CO, mice. Data are 
presented as the means ± S.E.M.  
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Figure 2 
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Figure 5 
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Figure 6 
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Figure 7 
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